300676.SZ SHZ
BGI Genomics Co., Ltd.
1W: +4.7%
1M: +17.9%
3M: +27.9%
YTD: -8.0%
1Y: -12.1%
3Y: -22.2%
5Y: -58.8%
¥45.86 ($6.84)
+1.70 (+3.85%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$3.9B
-11.1% ▼
5Y CAGR: +6.7%
Gross Profit
$1.5B
-30.0% ▼
5Y CAGR: +0.0%
Operating Income
-$875M
-680.7% ▼
Net Income
-$903M
-1071.7% ▼
EPS (Diluted)
$-2.19
-1072.0% ▼
EBITDA
-$321M
-166.5% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $8.4B | $6.8B | $7.1B | $4.3B | $3.9B |
| YoY Growth | +199.9% | -19.4% | +4.2% | -38.3% | -11.1% |
| Cost of Revenue | $3.4B | $2.8B | $3.5B | $2.2B | $2.4B |
| Gross Profit | $5.0B | $3.9B | $3.5B | $2.1B | $1.5B |
| Gross Margin | 59.7% | 57.9% | 50.0% | 49.4% | 38.9% |
| R&D Expenses | $620M | $487M | $536M | $529M | $606M |
| SG&A Expenses | $1.6B | $1.6B | $2.0B | $1.4B | $1.4B |
| Operating Expenses | $2.5B | $2.1B | $2.4B | $2.0B | $2.4B |
| Operating Income | $2.5B | $1.8B | $1.1B | $151M | -$875M |
| Operating Margin | 29.7% | 26.9% | 15.4% | 3.5% | -22.6% |
| Interest Expense | $92M | $109M | $106M | $95M | $56M |
| Income Before Tax | $2.4B | $1.7B | $1.0B | $116M | -$886M |
| Tax Expense | $340M | $268M | $198M | $22M | $26M |
| Net Income | $2.1B | $1.5B | $803M | $93M | -$903M |
| Net Margin | 24.9% | 21.6% | 11.4% | 2.1% | -23.3% |
| EPS (Diluted) | $5.24 | $3.55 | $1.96 | $0.23 | $-2.19 |
| EBITDA | $2.9B | $2.0B | $1.3B | $483M | -$321M |
| Shares Outstanding | 399M | 412M | 410M | 412M | 412M |